argenx (ARGX) Announces Strategic Priorities for 2022
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- Wall Street ends down as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- Wall Street ends down as oil prices, Treasury yields rise
- Anthropic's Claude AI identifies novel enzyme system in DNA search
- AppLovin (APP) on watch amid 3% drop premarket as boutique comments circulate
- Plug Power COO resigns to join another company
- Xtend AI Robotics wins Phase III of USSOCOM lethal drone program
argenx Highlights Strategic Priorities for 2022
January 7, 2022 1:00 AM ESTInitiated global VYVGART (efgartigimod alfa-fcab) commercial launch
Expect data from five registrational trials of efgartigimod by first quarter of 2023
Announcing four new efgartigimod indications to be initiated in 2022: membranous nephropathy, lupus nephritis, Sjogrens syndrome, COVID-19 mediated postural orthostatic tachycardia syndrome (POTS)
Anticipate clinical development programs in 12 autoimmune conditions across four therapeutic franchises by end of 2022
Management to present at 40th Annual J.P. Morgan Healthcare Conference
BREDA, Netherlands--(BUSINESS WIRE)-- Regulatory News:
argenx (Euronext & Nasdaq:... More
